Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Resunab Fast Tracked to Treat Scleroderma, Plus, Infliximab Biosimilars in Europe

Michele B. Kaufman, PharmD, BCGP  |  September 2, 2015

GENERIC_Drugs_500x270Resunab for Systemic Sclerosis Receives FDA Fast-Track Status
Systemic sclerosis (scleroderma) affects mostly women in mid-life and is a rare, serious and chronic autoimmune disorder. There are no treatments approved by the FDA, and the disease confers significant morbidity and mortality.

Resunab has received FDA fast-track development status for treating systemic sclerosis.1 It entered Phase 2 clinical trials, in a double-blind, randomized, placebo-controlled study, which began in June, to evaluate its safety, tolerability, pharmacokinetics and efficacy in 36 patients aged 18–70 years with active diffuse cutaneous systemic sclerosis.2

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Resunab is a novel, synthetic, oral endocannabinoid drug, which mimics the pharmacological effects of cannabinoids. It specifically binds to CB2 receptors on immune cells and fibroblasts. Non-clinical studies have shown that when resunab binds to CB2 it activates the production of specialized pro-resolving lipid mediators (SPMs), which stimulate an endogenous cascade accountable for resolving fibrosis and inflammation. The outcome of this cascade restores chronically activated immune systems back to homeostasis, while halting fibrosis and without causing immunosuppression.

Use of Infliximab Biosimilars Continues to Expand Abroad
In July, the central purchasing agency for Assistance Publique-Hôpitaux de Paris (AP-HP) selected the biosimilar infliximab to treat the hospital group’s patients with rheumatoid arthritis, Crohn’s disease and psoriasis—after a 45% discount on Inflectra (biosimilar infliximab, Hospira) was offered by the manufacturer. The decision by the hospital group was made in an effort to reduce drug spending.3,4 The innovator product Remicade will continue to be used on patients who are already being treated with infliximab. However, all infliximab-naive patients will be started on Inflectra (biosimilar infliximab). Quality, effectiveness and medication safety continue to be priorities in treating patients and will be closely monitored in all treated patients.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. Corbus Pharmaceuticals Holdings Inc. News release: Corbus Pharmaceuticals’ investigational drug resunab granted fast-track status by the U.S. FDA for the treatment of systemic sclerosis. 2015 Aug 19.
  2. U.S. National Institutes of Health. Study record detail: Safety, tolerability, efficacy and pharmacokinetics of JBT-101 in systemic sclerosis. 2015 Aug 25.
  3. Blamont M. Exclusive: Hospira wins French biosimilar drug tender at 45% discount. Reuters. 2015 July 3.
  4. Generics and Biosimilars Initiative. News release: Biosimilar infliximab offered to French hospitals at 45% discount. 2015 July 31.

Share: 

Filed under:Biologics/DMARDsDrug Updates Tagged with:infliximab

Related Articles

    Possible Impact of Biosimilar Infliximab on U.S. Market in Prescriptions, Pricing

    September 8, 2016

    paulista/shutterstock.com The use of biosimilars for rheuma­tology in the U.S. became a reality when the U.S. Food and Drug Administration (FDA) approved Inflectra (infliximab-dyyb), a biosimilar to Remicade (infliximab), in April. What this may mean is increased competition among drug companies with regard to pricing and, therefore, potentially lower costs for U.S. patients, according to…

    Medicalwriters/Science Source

    Biosimilars Are Slowly Climbing Toward Acceptance in Rheumatology

    June 15, 2020

    As useful stand-ins for biologics targeting a range of inflammatory diseases, biosimilars have made significant inroads across Europe as less expensive alternatives. Denmark, for example, realized a cost savings of 64% after instituting a mandatory national switch from the originator infliximab to its biosimilar counterpart. In the U.S., however, a considerably smaller fraction of rheumatologists…

    Biosimilars Great Debate: To Switch or Not?

    November 17, 2017

    SAN DIEGO—Should patients with rheumatic diseases switch from a biologic to its biosimilar? At the 2017 ACR/ARHP Annual Meeting’s Great Debate, held Nov. 5, two rheumatologists argued whether to switch or stay put based on safety, efficacy and potential cost savings. First to the podium to make the case for switching, Jonathan Kay, MD, tweaked…

    Should Patients with Rheumatic Disease Switch from Biologic to Biosimilar?

    January 19, 2018

    Should patients with rheumatic diseases switch from a biologic to its biosimilar? Lightspring / shutterstock.com SAN DIEGO—Should patients with rheumatic diseases switch from a biologic to its biosimilar? At the 2017 ACR/ARHP Annual Meeting’s Great Debate, held Nov. 5, two rheumatologists argued whether to switch or stay put based on safety, efficacy and potential cost…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences